Oppenheimer analyst Jay Olson maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $200 to $216.
Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $216
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.